Introduction {#sec1-1}
============

Acute monoblastic/monocytic leukemia (AMoL) is recognized by the 2016 WHO classification as a not specific subtype, NOS (not otherwise specified), of acute leukemias.^[@ref1]^ According to the FAB (French- American-British) classification, AMoL M5a is a subtype characterized by proliferation of monoblasts, which account for at least 80% of leukemic cells.^[@ref2],[@ref3]^

A morphologic diagnosis of AMoL is difficult, because monoblasts generally are poorly differentiated cells and can be confused with large lymphomatous cells,^[@ref4]^ or other immature cells, such as plasma blasts,^[@ref5],[@ref6]^ or very immature erythroblasts.^[@ref7]^

Monoblasts can be defined as large cells (20-30 μm), with round/oval nuclear shape, delicate chromatin, prominent nucleolus, basophilic cytoplasm with few azurophilic granules.^[@ref8]^ Cytochemical staining, such as either alpha-naphtyl-acetate esterase (ANAE) or alpha-naphtyl-butirate esterase (ANBE) can be used to identify monocytes and their neoplastic counterparts. Although more sensitive than ANBE, ANAE can be negative in about 20% of cases of AMoL.^[@ref9]^

Flow cytometry has an essential role in the diagnosis and classification of acute leukemia.^[@ref10]^ Monoblasts are identified by means of CD (cluster of differentiation) markers which are relatively characteristic of the monocytic lineage. Using multiparameter flow cytometry (MFC) and a broad monoclonal antibody (MoAb) panel, the diagnosis of AMoL can be established in a very high percentage of cases. The most useful CD markers are CD13, CD33, CD15, CD64, CD65s and HLA-DR,^[@ref2],[@ref9],[@ref11],[@ref12]^ which are positive in the vast majority of cases.

In the current paper we describe a peculiar case of AMoL with a very undifferentiated morphology of blast cells, which mimicked plasma blasts or erythroid blasts, and with high percentage of blasts positive for the erythroid markers CD71 and Glycophorin-A. To the best of our knowledge, the positivity of Glycophorin-A in AMoL has not been reported previously.

Case Report {#sec1-2}
===========

A Caucasian 41-year-old female, with a previous silent clinical history, complained of fatigue and exertional dyspnea. After a family doctor visit, she carried out a complete blood count (CBC) and chemistries. CBC showed Hb 8.5 g/dL; WBC 8x10^9^/L; PLT 50x10^9^/L. Automated differential of WBC showed an apparent lymphocytosis (60%), but manual differential, carried out in the Central Laboratory of Clinical Pathology of our Hospital, was consistent with a possible plasma blast leukemia or, in alternative, with a possible derivation of blasts from the erythroid lineage ([Figure 1](#fig001){ref-type="fig"}). Chemistries showed very high LDH values (2,000 U/L). Blood coagulation parameters were normal, as well as the electrophoretic protidogram and immunoglobulin levels. Serum immunofixation did not show any monoclonal component.

The patient was sent to our observation. Ultrasound and TC scans did not show lymphadenomegalies nor hepatosplenomegaly.

A myeloaspirate was carried out. Bone marrow aspirate films showed hypercellularity due to massive infiltration by medium- sized to large-sized blasts, with round and often eccentric nucleus, loose chromatin, abundant basophilic cytoplasm and, often, a perinuclear "hof" ([Figure 2A](#fig002){ref-type="fig"}). Binuclear cells with erythroblast-like morphology were observed ([Figure 2B](#fig002){ref-type="fig"}), as well as occasional cells with cytoplasmic bridges ([Figure 2C](#fig002){ref-type="fig"}). Morphology was compatible with: plasma blasts, early erythroid precursors, monoblasts. Myeloperoxidase (MPO; benzidine-based assay) showed few positive cells, while ANAE (diagnostic kit purchased from Sigma-Aldrich, Saint Louis, MO, USA), was strongly positive, with prevalent diffuse pattern, in about 80% of neoplastic cells ([Figure 2D](#fig002){ref-type="fig"}). These results were compatible with AMoL, M5a subtype of FAB classification.

Bone marrow samples were subjected to immunophenotyping by MFC, which was performed by a FacsCanto II cytometer (Becton Dickinson, BD, Palo Alto, CA, USA) equipped with three lasers (405, 488 and 633 nm) and assisted by the FacsDiva software (BD). A 6-8 color method was carried out, using MoAbs conjugated with the following fluorochromes: FITC, PE, PerCP-Cy5.5, PE-Cy.7, APC, APC-Cy7, Horizon V450, Horizon V-500. All MoAbs were purchased from BD. A lyse-no-wash method was used, and erythrocyte lysing was made by NH^4^Cl. Fifty μL/tube of bone marrow samples was incubated with adequate amounts of MoAbs (7 μL for FITC and PE, 5 μL for the other MoAbs) for 20 minutes at room temperature in the dark. One hundred thousand events /tube were acquired for the cytofluorimetric analysis.

Blast cells were found in the monocytic area of the CD45/SSC dot-plot. They were positive for CD33, CD15, CD38, CD56, CD64, HLA-DR, CD4 ([Figure 3](#fig003){ref-type="fig"}), with a homogeneous pattern of positivity and high fluorescence intensity; low fluorescence intensity was found for CD14 and CD71 ([Figure 3C](#fig003){ref-type="fig"} and I), while CD13 was downregulated ([Figure 3D](#fig003){ref-type="fig"}). Interestingly, Glycophorin-A was found to be positive in 60% of blast cells, with high fluorescence intensity ([Figure 3I](#fig003){ref-type="fig"}). Blast cells were negative for CD138, and very few events positive for both CD138 and CD38 were found, being classified as residual plasma cells ([Figure 3L](#fig003){ref-type="fig"}). Residual lymphocytes were used as internal control and quadrant analysis was performed using lymphocyte fluorescence intensity as a negative control.

Molecular biology assays carried out by polymerase chain reaction (PCR) methods, using the diagnostic kits REALQUALITY RQ-BCR-ABL p210, REALQUALITY RQ-BCR-ABL p210, REALQUALITY RSPML- RARa bcr1, REALQUALITY RSPML- RARa bcr3, REALQUALITY RSAML1- ETO and REALQUALITY RSINV16 (AB Analitica, Padua, Italy) resulted negative for the following fusion-genes: BCR-ABL1, AML1-ETO, PML-RARα, CBFβ-MYH11.

After G-banding technique usage, a karyotype with 47,XX,+8,del(20q) was detected.

As a result of the above findings, AMoL with aberrant expression of Glycophorin-A was diagnosed.

The patient gave her informed consent to personal data treatment and to diagnostic and therapeutic procedures

Discussion and Conclusions {#sec1-3}
==========================

A morphologic diagnosis of AMoL is very difficult, mostly in the case of the M5a subtype of the FAB classification. In this subtype of acute leukemia, blasts share many features with other immature cells, such as plasma blasts and very early erythroblasts. ^[@ref5]^ Enzyme cytochemistry is able to detect cells deriving from the monocytic lineage, ANAE being more sensitive than ANBE.^[@ref9]^ In our case, ANAE was able to identify AMoL, despite the very immature morphology of blast cells.

MFC is the most useful method to detect monoblasts. About 100% of cases are positive for CD13, CD33, HLA-DR, and 56-85% of cases are positive for CD4, CD11b, CD11c, CD14, CD15, CD56, CD64. Other molecules, such as CD34 and CD117 are less frequently expressed by blasts from AMoL (11-45% of cases).^[@ref2],[@ref9],[@ref11]^ Therefore, by using MFC and a wide MoAb panel, it is possible to identify leukemic monoblasts and diagnose AMoL, even in cases negative for ANAE and/or ANBE.^[@ref16]^

In our case, blast cells showed a very undifferentiated morphology and differential diagnoses involved either plasma blast leukemia or erythroid leukemia blasts. However, both cytochemistry and MFC were able to clearly diagnose AMoL.

Interestingly, in our case both CD71 and Glycophorin-A were detected. CD71 is a membranous protein involved in iron uptake and, since most body iron is used by erythroid cells for hemoglobin synthesis, it appears at a very early stage of erythroid development.^[@ref17]^ This molecule can be used to study the maturation of the erythroid lineage in bone marrow samples: the expression of CD71 is found in pro-erythroblasts and maturating erythroblasts, and is lost when also the nucleus is lost by the orthochromatophilic normoblasts.^[@ref18]^ CD71, however, is expressed in many cases of acute myeloid leukemia, with low levels of fluorescence intensity in cases of AMoL.^[@ref19]^ Its presence could be related to a high cell proliferative rate. However, some studies have shown that neither citofluorimetric positivity nor the amounts of the specific transferrin mRNA had any correlation with outcome.^[@ref19],[@ref23],[@ref24]^

Glycophorin-A (also termed CD235a) is the major glycophorin of human erythroid lineage and is involved in carrying some blood group antigens.^[@ref24]^ This molecule is a very specific marker of the erythroid lineage^[@ref18],[@ref26]^ and, in combination with CD71, as well as others molecules, is useful to study the maturation of the erythroid lineage, since its expression characterizes intermediate and late stages of normal erythroid maturation. ^[@ref18],[@ref26]^ In addition, Glycophorin-A is a very important diagnostic marker of acute erythroid leukemia,^[@ref12],[@ref15],[@ref27],[@ref28]^ being positive in many cases.

In our case, a high percentage of monoblasts were positive for Glycophorin- A and, to the best of our knowledge and after an extensive search of the literature available in PubMed archives, its positivity in AMoL has never been described previously.

We hypothesize that Glycophorin-A positivity in a case of AMoL could be explained as derivation of blast cells from a common myelo-erythroid precursor. In fact, according to the myeloid-based model of myelopoiesis, myeloid cells represent a prototype of blood cells, whereas erythroid, T and B cells represent specialized types.^[@ref29]^ Thus, a common myelo-erythroid precursor is likely to derive from hematopoietic stem cells.^[@ref17],[@ref29]^ undergoing subsequent separate differentiation into myeloid precursor cells and erythroid precursor cells. According to such a model, in our case the leukemogenic events could have interested a common myelo-erythroid precursor soon before the production of committed cells with different differentiation properties. Such a hypothesis could explain the permanence of Glycophorin-A on the majority of leukemic cells belonging to the monocytic lineage.

Interestingly, according to the model proposed by Mori *et al.*,^[@ref17]^ the common myeloid-erythroid precursor might develop towards the erythroid-megakaryocytic lineage after up-regulation of CD71 and towards the myeloid lineage if CD71 remains down-regulated.

Finally, the co-existence of an erythroid molecule with myelo-monocytic markers might represent a very powerful leukemiaassociated immunophenotype, useful to assess response to therapy and to evaluate minimal residual disease.

![Morphology of circulating blast cells (May-Grünwald-Giemsa; x1,000).](hr-10-4-7823-g001){#fig001}

![Morphology of myeloaspirate samples. A) massive infiltration by medium- and large-sized blast cells with undifferentiated morphology, often with a perinuclear "hof ". B) a binuclear blast with erythroblast-like morphology (arrow). C) two blast cells linked by a cytoplasmic bridge (arrow). D) most of blast cells are positive for ANAE, with a homogeneous pattern of staining; x1,000).](hr-10-4-7823-g002){#fig002}

![Flow cytometric immunophenotyping of bone marrow, quadrant analysis. A) CD45/SSC properties of blast cells. B) gating of blast cells (P1, red dots) and residual lymphocytes (P2, blue dots). C-H) pattern of expression of monocytic and myeloid markers. I) co-expression of CD71 (with low fluorescence intensity) and Glycophorin-A (which is positive in 60% of blast cells). L) detection of a very small plasma cell population.](hr-10-4-7823-g003){#fig003}
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